Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Carlos J Camacho"'
Autor:
Nicolas A Pabon, Yan Xia, Samuel K Estabrooks, Zhaofeng Ye, Amanda K Herbrand, Evelyn Süß, Ricardo M Biondi, Victoria A Assimon, Jason E Gestwicki, Jeffrey L Brodsky, Carlos J Camacho, Ziv Bar-Joseph
Publikováno v:
PLoS Computational Biology, Vol 14, Iss 12, p e1006651 (2018)
An expanded chemical space is essential for improved identification of small molecules for emerging therapeutic targets. However, the identification of targets for novel compounds is biased towards the synthesis of known scaffolds that bind familiar
Externí odkaz:
https://doaj.org/article/34634c75dc7c43d1b7435c229390e398
Autor:
Nicolas A Pabon, Carlos J Camacho
Publikováno v:
eLife, Vol 6 (2017)
Many eukaryotic regulatory proteins adopt distinct bound and unbound conformations, and use this structural flexibility to bind specifically to multiple partners. However, we lack an understanding of how an interface can select some ligands, but not
Externí odkaz:
https://doaj.org/article/b6d5b60c143c4276a9c3fadbeb895f28
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134697 (2015)
The 2012 Teach-Discover-Treat (TDT) community-wide experiment provided a unique opportunity to test prospective virtual screening protocols targeting the anti-malarial target dihydroorotate dehydrogenase (DHODH). Facilitated by ZincPharmer, an open a
Externí odkaz:
https://doaj.org/article/2535138dc58f4793ac479def18e2ffe8
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0133590 (2015)
The ABL protein-tyrosine kinase regulates intracellular signaling pathways controlling diverse cellular processes and contributes to several forms of cancer. The kinase activity of ABL is repressed by intramolecular interactions involving its regulat
Externí odkaz:
https://doaj.org/article/9862d2a7771c43dc84adcbdd37ab91e0
Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists.
Autor:
David Koes, Kareem Khoury, Yijun Huang, Wei Wang, Michal Bista, Grzegorz M Popowicz, Siglinde Wolf, Tad A Holak, Alexander Dömling, Carlos J Camacho
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e32839 (2012)
Although there is no shortage of potential drug targets, there are only a handful known low-molecular-weight inhibitors of protein-protein interactions (PPIs). One problem is that current efforts are dominated by low-yield high-throughput screening,
Externí odkaz:
https://doaj.org/article/bfa426538b5d4582a9e9ca13d85e2907
Publikováno v:
PLoS Computational Biology, Vol 4, Iss 11, p e1000231 (2008)
In the conventional paradigm of humoral immunity, B cells recognize their cognate antigen target in its native form. However, it is well known that relatively unstable peptides bearing only partial structural resemblance to the native protein can tri
Externí odkaz:
https://doaj.org/article/b3d18e23464246cbad73b88fdc3002a6
Autor:
Carlos J Camacho
Publikováno v:
PLoS ONE, Vol 3, Iss 10, p e3342 (2008)
Ion channels play a central role in setting gradients of ion concentration and electrostatic potentials, which in turn regulate sensory systems and other functions. Based on the structure of the open configuration of the Kv1.2 channel and the suggest
Externí odkaz:
https://doaj.org/article/c614d597d56d47989765d3a11d6a08bd
Autor:
Ashley T. Fancher, Yun Hua, David A. Close, Wei Xu, Lee A. McDermott, Christopher J. Strock, Ulises Santiago, Carlos J. Camacho, Paul A. Johnston
Publikováno v:
SLAS Discovery, Vol 28, Iss 7, Pp 325-343 (2023)
Three series of compounds were prioritized from a high content screening campaign that identified molecules that blocked dihydrotestosterone (DHT) induced formation of Androgen Receptor (AR) protein-protein interactions (PPIs) with the Transcriptiona
Externí odkaz:
https://doaj.org/article/1f522784d4774c6bb7d40f6419a475d6
Autor:
Andrew M. Asberry, Xinpei Cai, Xuehong Deng, Ulises Santiago, Sheng Liu, Hunter S. Sims, Weida Liang, Xueyong Xu, Jun Wan, Wen Jiang, Carlos J. Camacho, Mingji Dai, Chang-Deng Hu
Publikováno v:
Journal of Medicinal Chemistry. 65:13793-13812
Protein arginine methyltransferase 5 (PRMT5) is a master epigenetic regulator and an extensively validated therapeutic target in multiple cancers. Notably, PRMT5 is the only PRMT that requires an obligate cofactor, methylosome protein 50 (MEP50), to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f803b5f054093aa4bbcc6fa4cc1b8a69
https://doi.org/10.1021/acs.jmedchem.2c01000
https://doi.org/10.1021/acs.jmedchem.2c01000
Autor:
Kimberly Gomez, Ulises Santiago, Aida Calderon-Rivera, Paz Duran, Santiago Loya-Lopez, Dongzhi Ran, Samantha Perez-Miller, Handoko Handoko, Paramjit S. Arora, Marcel Patek, Tamara D. King, Huijuan Hu, Carlos J. Camacho, Rajesh Khanna
Publikováno v:
The Journal of Pain. 24:32-33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c793f22925f677e1a64c9e45f198894
https://doi.org/10.1016/j.jpain.2023.02.106
https://doi.org/10.1016/j.jpain.2023.02.106